XNTR-20-02 Study Update

by | Jun 2, 2022 | Latest News

Sydney, Australia, CHICAGO, Ill USA and GYEONGGI-DO, South Korea. Today, Xennials Therapeutics Australia Pty, Ltd., subsidiary of Xennials Therapeutics, Inc., a clinical stage biotechnology company dedicated to the development of transformative therapies and platforms...

Xennials Therapeutics Australia Pty Ltd, in collaboration with PinotBio Inc., announces the enrollment of First patient in to the Phase 1/2 study of NTX-301 as a single agent and in combination with Standard of Care in selected solid tumors

by | Sep 2, 2021 | Latest News

Sydney, Australia, CHICAGO, Ill USA and Gyeonggi-do, South Korea. September 02, 2021. Today, Xennials Therapeutics Australia Pty, Ltd., subsidiary of Xennials Therapeutics, Inc., a clinical stage biotechnology company dedicated to the development of transformative...

Xennials Therapeutics Australia Pty Ltd, in collaboration with PinotBio Inc., announces the start of a new Phase 1/2 study of NTX-301 as a single agent and in combination with Standard of Care in selected solid tumors

by | May 3, 2021 | Latest News

Sydney, Australia, CHICAGO, Ill USA and Gyeonggi-do, South Korea. May 03, 2021. Today, Xennials Therapeutics Australia Pty, Ltd., subsidiary of Xennials Therapeutics, Inc., a clinical stage biotechnology company dedicated to the development of transformative therapies...